MorphoSys AG
Lena-Christ-Strasse 48
Martinsried
Munich
82152
Germany
Tel: 49-0-89-899-27-0
Fax: 49-0-89-899-27-222
Website: http://www.morphosys.com/
Email: info@morphosys.com
560 articles about MorphoSys AG
-
Invitation to MorphoSys' Third Quarter and First 9-Month 2020 Results Conference Call on November 12, 2020
11/4/2020
MorphoSys AG will publish its results for the third quarter and first 9-month of 2020 on November 11, 2020 at 10:00pm CET.
-
MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition
11/4/2020
MorphoSys AG Prime Standard Segment; MDAX & TecDAX; announced that multiple abstracts regarding the company's proprietary key asset tafasitamab have been accepted for poster presentations and online publication at the upcoming 62nd ASH Virtual Annual Meeting and Exposition from December 05-December 08, 2020.
-
MorphoSys AG Raises its Financial Guidance for the Full Year 2020
10/27/2020
MorphoSys AG ; Prime Standard Segment; MDAX & TecDAX; announces an increase in its financial guidance for the financial year 2020 after preliminary completion of the latest evaluation of MorphoSys' financial performance.
-
MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)
10/19/2020
MorphoSys AG announced that its licensee Janssen Research & Development, LLC. has announced it received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending the expanded use of Tremfya for the treatment of adult patients with active psoriatic arthritis in the European Union.
-
MorphoSys AG Launches an Offering of Approx. EUR 325 Million Convertible Bonds
10/13/2020
MorphoSys AGtoday announces to launch an offering of unsubordinated, unsecured convertible bonds due 2025 in an aggregate principal amount of approximately EUR 325 million.
-
MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
9/17/2020
Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST
-
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
9/17/2020
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors.
-
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
-
BioSpace Global Roundup, Aug. 20
8/20/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
8/18/2020
MorphoSys AG and Incyte announced that Monjuvi®, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas.
-
MorphoSys Reports Second Quarter and First Half 2020 Results
8/5/2020
MorphoSys AG reports results for the second quarter and first half of 2020.
-
Eight months after inking a collaboration deal, MorphoSys and Incyte won approval for Monjuvi for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
-
FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
8/1/2020
First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need
-
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
7/31/2020
First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need
-
RegulatoryMorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
7/31/2020
MorphoSys AG announces that the U.S. Food and Drug Administration has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
-
Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020
7/30/2020
Invitation to MorphoSys; Second Quarter and First Half 2020 Results Conference Call on August 6, 2020 MorphoSys AG
-
MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis
7/14/2020
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 14, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announced today that its licensee Janssen Research & Development, LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) approval of Tremfya (R) (guselkumab) as a treatment for adult patients living with active psoriatic arthritis (PsA). Active PsA is a chronic progressive disease characterized by painful joints and skin inflammation. A
-
MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL
5/18/2020
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today reported updated results from the ongoing Phase 2 L-MIND study investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
-
Clinical Catch-Up: May 11-15
5/18/2020
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look. -
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
4/27/2020
I-Mab and MorphoSys AG jointly announced that the first patient has been dosed in a phase 3 clinical study in mainland China to evaluate MorphoSys’ investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.